Abstract
Although the clinical syndrome of paroxysmal nocturnal hemoglobinuria (PNH)' was recognized many years ago (1), its complexity was difficult to explain. The erythrocytes were known to be susceptible to the hemolytic action of complement , and this characteristic formed the basis for the diagnosis of the disease (2). In addition, many patients suffered thromboses and/or had evidence of relative or absolute diminution in hematopoiesis (3). Although the disease appeared to be acquired, no specific lesion could be delineated which could account for the complex clinical symptoms. The first identified biochemical defects were the absence of two enzymes: acetylcholinesterase from the red cells (4) and alkaline phosphatase from the leukocytes (5, 6). Considerably later, the absence of the complement regulatory protein, decay accelerating factor (DAF), was identified (7). To date, at least 14 proteins have been found to be missing or markedly diminished on the abnormal blood cells in PNH (Table I). For many of these, functions are known, and the lack of those functions may be related to the pathogenesis of PNH; in other cases, the function of the missing protein is not known. Further, it is likely that other proteins, as yet unidentified, are probably also missing. The recognition, first, that alkaline phosphatase (8) and, later, that DAF (9) were tethered to the plasma membrane by a glycosylphosphatidylinositol anchor directed research on the pathogenesis of the defects in PNH to the biosynthesis of that molecule. The glycosylphosphatidylinositol anchor and its biosynthesis A large number of eukaryotic proteins are attached to the cell surface by novel glycolipids called glycosylphosphatidylinosi-tols (GPIs) (10-13). This type of glycolipid constitutes

This publication has 77 references indexed in Scilit: